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Breaching the Placenta
Fast Fetal Absorption of a Common Compound
Most maternally administered chemicals have the potential to cross
the placental barrier, and the question is not whether a chemical
crosses the placenta, but the rate at which it does so. In this issue,
Osamu Takahashi and Shinshi Oishi of the Tokyo Metropolitan
Research Laboratory of Public Health present their findings that the
placenta fails to act as a barrier to a potentially toxic compound,
2,2-bis(4-hydroxyphenyl)propane, also known as bisphenol A or
BPA [EHP 108:931–935]. The
researchers found that BPA can
be transferred across the placen-
tal barriers of female Fischer
344 rats to their fetuses. They
also discovered that BPA is
absorbed and distributed in
maternal internal organs and
fetuses extremely rapidly. 
BPA has been widely used
in plastics manufacture and as a
fungicide, antioxidant, flame
retardant, rubber chemical, and
polyvinyl chloride stabilizer.
The estimated production of
BPA in Japan in 1995 was
about 260,000 tons. Release
and migration of BPA from
various resins and plastic prod-
ucts into the environment have
been recognized; small amounts
of the compound are detectable
in river and tap water.
BPA has not been found to
be carcinogenic or teratogenic.
At doses of 5.0–6.3 grams per
kilogram per day (g/kg/day), it
is nephrotoxic in mice. Doses
of 400–1,000 milligrams
(mg)/kg/day of BPA have pro-
duced estrogenic activity in immature rats or female mice whose
ovaries have been surgically removed, and doses at 437–1,750
mg/kg/day have adversely affected the reproductive system and sperm
production in male mice. However, although lower doses (2–400
micrograms [µg]/kg/day) of BPA administered into the uterus through
the mother’s circulation have been reported to affect reproductive
organs in male offspring of mice and rats, scientists have to date been
unable to reproduce these results, so such toxicity remains controversial.
What impressed Takahashi and Oishi was the speed with which
BPA was transferred from the pregnant rat dam to her fetuses. On
day 18 of gestation, they administered 1 g/kg BPA dissolved in
propylene glycol at 25% weight per volume. This dose is about one-
fourth the median lethal dose for rats. It took only 20 minutes for
the BPA to attain its maximum concentrations in maternal blood,
liver, and kidneys (these concentrations were 14.7, 171.0, and 36.2
µg/g, respectively). Likewise, in 20 minutes, BPA concentration in
the fetuses reached its maximum at 9.22 µg/g. Six hours after
administration of BPA, its concentrations in the maternal blood and
organs and in the fetuses were reduced to 2–5% of maximum. In
the view of the authors, the attainment of maximum concentrations
of BPA in the mother rat and her fetuses suggests that BPA’s absorp-
tion and distribution are extremely rapid and that the placenta does
not act as a barrier to BPA.
One factor that determines whether a compound is absorbed by
the fetus are its lipophilic or hydrophilic properties—that is, whether
it dissolves better in a lipid or in water. Compounds with a high
octanol/water partition coefficient (Pow)—compounds that are more
lipophilic—cross slowly; examples are pentachlorophenol and DDT,
whose log Pow is 5.0–6.0 (such compounds, nevertheless, can be
accumulated). By contrast, chemicals with a lower log Pow, such as
diethylstilbestrol and salicylic acid, are more hydrophilic and they
more easily cross the placenta; their log Pow may vary between -0.9
and 5.0. (The log Pow of BPA, which crosses the placenta so rapidly,
is 3.3.) Takahashi and Oishi suggest that the speed and degree of
transplacental absorption may be mediated by the lipophilic or
hydrophilic properties of a chemical.
In the case of BPA, because the placenta essentially presents no
barrier, the compound was rapidly passed through and could show
toxicologic effects; yet in this study it largely cleared after several
hours. However, the BPA dose of 1 g/kg was quite high. When a
dose of 0.1 g/kg BPA was administered, its concentrations in the
mother and fetuses could be determined accurately only near peak
levels. –Julian Josephson
Vulnerability to Lead
Absorption Varies with Genotype
Genetic factors may modify the toxicokinetics of lead in humans—
that is, how lead is absorbed, distributed, metabolized, and excreted.
Attention has centered on the enzyme δ -aminolevulinic dehydratase
(ALAD), which is coded by a single gene with two alleles, ALAD1
and ALAD2. In this month’s issue, Brian S. Schwartz of the Johns
Hopkins School of Hygiene and Public Health and colleagues pre-
sent their study on the influence of polymorphisms in the ALAD
and vitamin D receptor (VDR) genes on concentrations of lead in
blood and the tibia, and the amount of lead chelatable with dimer-
captosuccinic acid (DMSA) and excreted in the urine [EHP
108:949–954]. Their results confirm past observations that the
ALAD gene modifies lead toxicokinetics and furnish new evidence
that the VDR gene does so as well. 
Earlier research established that ALAD is a principal lead-bind-
ing protein in red blood cells, and recent data suggest that polymor-
phisms in the VDR gene influence tibia lead concentrations. In
particular, the polymorphism denoted as BsmI has three genotypes,
designated as bb, Bb, and BB, that appear to be linked with lead
concentrations in bone.
In this study, 798 Korean lead workers and 135 controls without
occupational lead exposure provided blood samples, and blood lead
was assessed with an atomic absorption spectrometer. Tibia lead was
evaluated using 109Cd-induced X-ray fluorescence, and chelatable
lead was measured as a 4-hour urinary lead excretion after the study
subjects were orally dosed with DMSA. The scientists also completed
ALAD and VDR genotyping on the subjects. Whether the workers
used tobacco or alcohol was taken into account during statistical
analysis.
Adjusted analyses showed that subjects with the VDR B allele
had significantly higher blood and tibia lead concentrations and
greater excretion of lead after DMSA dosing than did those with the
VDR bb genotype. The effect of the VDR B allele on blood lead
concentrations turned out to be greater than that of the ALAD2
allele. However, the mechanisms by which these genes influence
blood lead concentrations probably differ, because ALAD2 and VDR
B were both associated with higher blood lead concentrations, but
only VDR B was associated with higher tibia lead concentrations and
greater lead excretion after DMSA dosing.
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Rapid dam–fetus transfer. It took
only 20 minutes for maternally in-
gested BPA to reach maximum con-
centration in fetal Fischer 344 rats.
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PAfter binding to the VDR, vitamin D is known to increase
intestinal absorption of lead. It is possible that the influence of vita-
min D on lead absorption from the gut differs by genotype, and that
people with the VDR B allele have greater absorption of lead via the
intestines and greater uptake and subsequent release of lead from
bone. The scientists note, however, that tibia lead measurements by
X-ray fluorescence were complicated by the fact that such analyses are
standardized to bone mineral content. Thus, higher tibia lead read-
ings could be attributed to higher lead content, lower calcium con-
tent, or both.
Subjects with the ALAD2 allele showed higher blood lead con-
centrations but no differences in tibia or chelatable lead concentra-
tions compared with subjects lacking this allele. The results reinforce
observations that the ALAD2 allele increases red blood cell binding of
lead, and so probably decreases the relative deposition of lead in criti-
cal target organs, possibly protecting against the toxicity of lead by
increasing the amount of lead excreted in urine.
All studies to date suggest that the ALAD1 allele is more likely to
confer health risks from lead exposure. The researchers also found
that lead workers homozygous for the ALAD1 allele were much less
likely to have the VDR bb genotype; the two genes are apparently
linked despite the fact that they are located on different chromo-
somes. Although the VDR gene may play a role in susceptibility to
the health effects of lead, there are not enough data to indicate
whether its polymorphisms will modify health risks, and if so, which
allele brings about such risks. Compared with controls, lead workers
seem to have a higher prevalence of ALAD2 and VDR B. It may be
that the ALAD2 and VDR B alleles are protective, and there might be
selection by genotype among lead workers—perhaps because workers
who become symptomatic upon exposure to lead would choose to
leave the occupation—but this speculation requires further study.
–Julian Josephson
A New View of ELF-EMFs
Are They Linked with Cancer Promotion? 
The debate over a possible link between cancer and extremely
low frequency electromagnetic fields (ELF-EMFs) began with
a 1979 study that found excess cancer in people who lived near
large electrical wires. It has continued through subsequent in
vitro, in vivo, and epidemiological studies that often produced
conflicting results. In this issue, Gang Chen of the
Department of Pediatrics and Human Development at
Michigan State University and colleagues used an experimental
model developed to test cancer-promoting chemicals to exam-
ine whether ELF-EMFs might play a role in cancer promotion
[EHP 108:967–972].
The development of cancer is a multistage process. During
normal development, immature cells undergo a process called
differentiation in which they become highly specialized (devel-
oping, for instance, into red blood cells) and are less able to
continue proliferating. In the first stage of cancer, initiation, a
cell’s DNA is damaged through mutation, causing a differenti-
ated cell to resemble an immature one, in effect reversing the
process of differentiation. In the second stage, promotion, nor-
mal cellular controls go awry, and the mutated cell multiplies.
ELF-EMFs are too weak to kill cells or (most scientists agree)
to cause mutations and thus initiate cancer. However, they
could play a role during the promotion stage of cancer, which
involves so-called epigenetic mechanisms (those that affect
gene expression rather than gene structure) and induce cancer
in cells that have already mutated. 
In the laboratory, differentiation—which can be stimulated by
chemical treatment—can transform initiated cells into mature cells,
converting cells that had started to become cancerous into normal-
seeming adult cells. In this case, differentiation seems to be a healing
process that nullifies the mutation. What the group was testing was
whether ELF-EMFs could prevent differentiation in cells that had start-
ed down the road to cancer. 
The research used mouse leukemia cells that, when treated with
dimethyl sulfoxide (DMSO), differentiate into red blood cells. The
researchers group compared control cells, cells treated with DMSO,
and cells treated with DMSO and maintained inside a culture chamber
exposed to a 60-hertz ELF-EMF at varying strengths. In a system used
to investigate the epigenetics of cancer promotion, the scientists mea-
sured three end points. Proliferation, or cell growth, was determined by
measuring DNA concentration. Differentiation was measured by
detecting hemoglobin, a sign that the cell had developed into a red
blood cell. Youthfulness was gauged by measuring telomerase, the
enzyme that builds telomeres, which keep chromosomes “young” and
able to divide.  
Starting at a threshold dose of about 20 milligauss (a measure of
the strength of the electrical field), the 60-hertz ELF-EMF caused a
dose-dependent reduction of differentiation, as well as an increase in
telomerase and proliferation. These effects resemble those of chemical
cancer promoters. (Under a power line, fields measure roughly 300
milligauss, and near home appliances they can exceed 1 gauss.) 
While the study showed that ELF-EMFs could conceivably play a
biological role in carcinogenesis, cancer-promoting chemicals require a
long exposure to promote cancer, and human exposures to ELF-EMFs
are hard to gauge. Because electric fields change so radically from point
to point, it’s too early to say if typical exposures actually promote can-
cer. But by stressing the importance of promotion, the study could
focus future research on the environmental health effects of ELF-
EMFs. –David J. Tenenbaum
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A different role for electromagnetic fields? A 1979 study found that children
who lived near power lines (and consequently had higher ELF-EMF exposures) had a
higher incidence of cancer. Although most scientists believe ELF-EMFs are too weak
to initiate cancer, new research suggests they could play a role as cancer promoters.